Clinical efficiency of rivaroxaban for prevention of thromboembolic complications in patients with high cardio-metabolic risk
Authors:
- 29 June 2026
- journal article
- Published by Joint Editorial Office of the Ministry of Internal Affairs of Russia in Medical Bulletin of the Ministry of Internal Affairs
- Vol. 2026 (2) , 52-58
Abstract
Thromboembolic complications in individuals with high cardiometabolic risk are among the leading causes of cardiovascular mortality in the world. Rivaroxaban is an oral inhibitor of factor X (Stuart-Prower factor) approved for prevention of thromboembolic complications in many countries. The article evaluates clinical efficiency of rivaroxaban in reducing the possibility of development of thromboembolic complications in patients with high cardiometabolic risk with non-valvular atrial fibrillation coupled with obesity, arterial hypertension and hyperlipidemia.Keywords
This publication has 12 references indexed in Scilit:
- Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significanceCardiovascular Diabetology, 2023
- Metabolic syndrome as a risk factor for oncogenesisRussian Journal of Preventive Medicine, 2023
- Obesity and risk of venous thromboembolic eventsRussian Journal of Preventive Medicine, 2022
- Prevention and Treatment of Atrial Fibrillation via Risk Factor ModificationThe American Journal of Cardiology, 2021
- Adipose tissue macrophages in aging-associated adipose tissue functionThe Journal of Physiological Sciences, 2021
- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart AssociationCirculation, 2019
- Epicardial Fat and Atrial Fibrillation: the Role of Profibrinogenic MediatorsKardiologiia, 2018
- EPICARDIAL OBESITY AS ONE OF THE MAIN CRITERIA FOR THE METABOLIC OBESE PHENOTYPE OF OBESITYSiberian Medical Review, 2017
- Pathogenic Mechanisms of Atrial Fibrillation in ObesityRational Pharmacotherapy in Cardiology, 2016
- Adipokine dysregulation, adipose tissue inflammation and metabolic syndromeMolecular and Cellular Endocrinology, 2010